TN2013000336A1 - 5s,8s)-3-(4'-chlor-3'-fluoro-4-methylbiphenyl-3-yl)-4-hydroxy-8-methoxy-1-azaspiro[4.5]dec-3-en-2-one (compound a) for therapy. - Google Patents

5s,8s)-3-(4'-chlor-3'-fluoro-4-methylbiphenyl-3-yl)-4-hydroxy-8-methoxy-1-azaspiro[4.5]dec-3-en-2-one (compound a) for therapy.

Info

Publication number
TN2013000336A1
TN2013000336A1 TNP2013000336A TN2013000336A TN2013000336A1 TN 2013000336 A1 TN2013000336 A1 TN 2013000336A1 TN P2013000336 A TNP2013000336 A TN P2013000336A TN 2013000336 A TN2013000336 A TN 2013000336A TN 2013000336 A1 TN2013000336 A1 TN 2013000336A1
Authority
TN
Tunisia
Prior art keywords
methylbiphenyl
azaspiro
chlor
fluoro
methoxy
Prior art date
Application number
TNP2013000336A
Other languages
English (en)
Inventor
Ningshu Liu
Kai Thede
Philip Lienau
Arne Scholz
Christoph-Stephan Hilger
Ulf Bömer
Maher Najjar
Knut Eis
Reiner Fischer
Wahed Ahmed Moradi
Original Assignee
Bayer Ip Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE102011011040A external-priority patent/DE102011011040A1/de
Application filed by Bayer Ip Gmbh filed Critical Bayer Ip Gmbh
Publication of TN2013000336A1 publication Critical patent/TN2013000336A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/54—Spiro-condensed
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
TNP2013000336A 2011-02-06 2013-08-05 5s,8s)-3-(4'-chlor-3'-fluoro-4-methylbiphenyl-3-yl)-4-hydroxy-8-methoxy-1-azaspiro[4.5]dec-3-en-2-one (compound a) for therapy. TN2013000336A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KW1411 2011-02-06
DE102011011040A DE102011011040A1 (de) 2011-02-08 2011-02-08 (5s,8s)-3-(4'-Chlor-3'-fluor-4-methylbiphenyl-3-yl)-4-hydroxy-8-methoxy-1-azaspiro[4.5]dec-3-en-2-on (Verbindung A) zur Therapie
PCT/EP2012/051895 WO2012104428A1 (fr) 2011-02-06 2012-02-03 Utilisation de (5s,8s)-3-(4'-chloro-3'-fluoro-4-méthylbiphényl-3-yl)-4-hydroxy- 8-méthoxy-1-azaspiro[4.5]décane-3-en-2-one (composé a) à des fins thérapeutiques

Publications (1)

Publication Number Publication Date
TN2013000336A1 true TN2013000336A1 (en) 2015-01-20

Family

ID=49485835

Family Applications (1)

Application Number Title Priority Date Filing Date
TNP2013000336A TN2013000336A1 (en) 2011-02-06 2013-08-05 5s,8s)-3-(4'-chlor-3'-fluoro-4-methylbiphenyl-3-yl)-4-hydroxy-8-methoxy-1-azaspiro[4.5]dec-3-en-2-one (compound a) for therapy.

Country Status (18)

Country Link
US (1) US9212140B2 (fr)
EP (1) EP2670408A1 (fr)
JP (1) JP2014504624A (fr)
KR (1) KR20140053844A (fr)
CN (1) CN103533932A (fr)
AP (1) AP2013007057A0 (fr)
AR (1) AR085146A1 (fr)
AU (1) AU2012213344A1 (fr)
BR (1) BR112013020015A2 (fr)
CA (1) CA2826515A1 (fr)
CL (1) CL2013002247A1 (fr)
EA (1) EA201391084A1 (fr)
IL (1) IL227804A0 (fr)
MA (1) MA34887B1 (fr)
MX (1) MX2013009065A (fr)
TN (1) TN2013000336A1 (fr)
TW (1) TW201240659A (fr)
WO (1) WO2012104428A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2923884A1 (fr) 2013-09-12 2015-03-19 Pfizer Inc. Utilisation d'inhibiteurs de l'acetyl-coa carboxylase pour traiter l'acne vulgaire

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR9507275A (pt) * 1994-04-05 1997-11-18 Bayer Ag 1h-3-aril-pirrolidina-2,4-dionas alcoxi-alquil-substituídas
DE19813354A1 (de) * 1998-03-26 1999-09-30 Bayer Ag Arylphenylsubstituierte cyclische Ketoenole
DE10201239A1 (de) * 2002-01-15 2003-07-24 Bayer Cropscience Ag Fungizide biphenylsubstituierte cyclische Ketoenole
DE102006057037A1 (de) * 2006-12-04 2008-06-05 Bayer Cropscience Ag cis-Alkoxyspirocyclische biphenylsubstituierte Tetramsäure-Derivate
UY31968A (es) * 2008-07-09 2010-01-29 Sanofi Aventis Nuevos derivados heterocíclicos, sus procesos para su preparación, y sus usos terapéuticos
DE102010008644A1 (de) * 2010-02-15 2011-08-18 Bayer Schering Pharma Aktiengesellschaft, 13353 Zyklische Ketoenole zur Therapie

Also Published As

Publication number Publication date
KR20140053844A (ko) 2014-05-08
TW201240659A (en) 2012-10-16
MA34887B1 (fr) 2014-02-01
BR112013020015A2 (pt) 2017-03-21
EP2670408A1 (fr) 2013-12-11
AU2012213344A1 (en) 2013-08-22
CN103533932A (zh) 2014-01-22
CL2013002247A1 (es) 2014-01-03
EA201391084A1 (ru) 2014-02-28
US9212140B2 (en) 2015-12-15
AP2013007057A0 (en) 2013-08-31
CA2826515A1 (fr) 2012-08-09
JP2014504624A (ja) 2014-02-24
AR085146A1 (es) 2013-09-11
MX2013009065A (es) 2013-10-01
US20140031407A1 (en) 2014-01-30
WO2012104428A1 (fr) 2012-08-09
IL227804A0 (en) 2013-09-30

Similar Documents

Publication Publication Date Title
WO2012045090A3 (fr) Utilisation thérapeutique d'un agoniste de tlr, et polythérapie
IN2012DN06720A (fr)
SG10201808102WA (en) Bicyclic heterocycle compounds and their uses in therapy
AU2011328009A8 (en) Compounds and methods for treating pain
NZ726488A (en) Compositions and methods for transmucosal absorption
MX2014002171A (es) Tratamientos de combinacion para hepatitis c.
WO2015054619A3 (fr) Utilisation d'un inhibiteur de pcsk9 pour traiter l'hyperlipidémie
MX345928B (es) Composiciones terapeuticamente activas y metodos de uso de las mismas.
IN2015DN00376A (fr)
MX2013011908A (es) Composiciones y usos terapeuticos de inhibidores de cinasa epsilon relacionados con cinasa i-kappa b (ikk) y cinasa 1 de union tank.
MX2014010590A (es) Terapia de combinacion para trastornos proliferativos.
MX2012012438A (es) Formulaciones farmaceuticas que comprenden pioglitazona y linagliptina.
MX369385B (es) Productos para cicatrizar heridas tisulares.
ES2397889A1 (es) PÉPTIDOS MODULADORES DE PGC-1Alfa.
MX2010005631A (es) Nuevos compuestos de hidrocarburo ciclicos para el tratamiento de enfermedades.
MX344238B (es) Compuestos de tetrazol y métodos para preparar y usar los mismos.
GB201111485D0 (en) Drug composition and its use in therapy
IN2015DN00450A (fr)
EP2582682A4 (fr) Procédés pour traiter une affection pulmonaire
PH12016502352A1 (en) Pharmaceutical composition
WO2012142615A3 (fr) Auranofine et analogues d'auranofine utiles pour traiter une maladie proliférative et des troubles prolifératifs
MX2014001393A (es) 3-(bifenil-3-il)-4-hidroxi-8-metoxi-1-azaespiro[4.5]dec-3-en-2-on as sustituidas.
WO2013071056A3 (fr) Polythérapie médicamenteuse pour le traitement de tumeurs solides
IL260078B (en) Therapy used to treat Gaucher disease
MX360409B (es) Terapia de combinacion de dosis fija para la enfermedad de parkinson.